Amphion Partner, Motif, Poised to Help Solve Global Health Crisis

London and New York, 8 July 2014: Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, notes Prime Minister David Cameron’s 2 July 2014 statement pertaining to the launch of a new global taskforce, established to coordinate an international effort to combat antibiotic resistant superbugs.  The taskforce, which is to be chaired by economist Jim O’Neill, will focus on how to find and develop new drugs, specifically antibiotics, in order to combat the ever-growing and serious problem of these antibiotic resistant superbugs. 

Prime Minister David Cameron commented: “Resistance to antibiotics is now a very real and worrying threat as bacteria mutate to become immune to their effects.  With some 25,000 people a year already dying of infections resistant to antibiotic drugs in Europe alone, this is not some distant threat but something happening right now.  If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back to the dark ages of medicine where treatable infections and injuries can kill once again” - Source: 2 July 2014 Wellcome Trust Press Release   

Amphion’s Partner Company, Motif BioSciences Ltd. (“Motif”), a cutting-edge drug discovery/development company based in New York City, has a stated mission to develop solutions addressing the antibiotic crisis.  Motif is currently developing two new antibiotics that work in different ways to those commonly used today.  In the opinion of the management team, no other company worldwide is currently developing antibiotics with the same mechanism.  The highly experienced scientific team at Motif believes that these two new antibiotics will be particularly well equipped for commercial success.  Motif’s target is to have two new antibiotics ready to launch to the healthcare market and the management team looks forward to providing an update on details and timing in due course. 

Amphion’s Chief Executive Officer and Chairman of Motif, Richard Morgan, said: “We welcome the recent remarks made by Prime Minister Cameron regarding the antibiotic crisis and the initiatives he announced.  With its leading team of experts, strategic partnerships, and new antibiotic candidates, Motif is poised to help address this situation. 

“Amphion is currently the largest outside shareholder in Motif, which is second in size and importance in terms of our investment holdings.  We look forward to seeing the company progress its development programmes and believe the upside potential to be very large if the company is successful.”

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Novella Communications
Tim Robertson / Ben Heath
+44 020 3151 7008

Panmure Gordon Limited
Freddy Crossley / Grishma Patel (Corporate Finance)
Charlie Leigh-Pemberton(Corporate Broking)
+44 020 7886 2500

About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web:

On the web: